These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31415033)

  • 21. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
    Kirk AD; Adams AB; Durrbach A; Ford ML; Hildeman DA; Larsen CP; Vincenti F; Wojciechowski D; Woodle ES
    Am J Transplant; 2021 May; 21(5):1691-1698. PubMed ID: 33128812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial.
    Woodle ES; Kaufman DB; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
    Am J Transplant; 2020 Apr; 20(4):1039-1055. PubMed ID: 31680394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of acute rejection after rescue with Belatacept by association of low-dose Tacrolimus maintenance in medically complex kidney transplant recipients with early or late graft dysfunction.
    Gallo E; Abbasciano I; Mingozzi S; Lavacca A; Presta R; Bruno S; Deambrosis I; Barreca A; Romagnoli R; Mella A; Fop F; Biancone L
    PLoS One; 2020; 15(10):e0240335. PubMed ID: 33057374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effect of ASP2409, a Novel CD86-Selective Variant of CTLA4-Ig, on Renal Allograft Rejection in Nonhuman Primates.
    Oshima S; Karrer EE; Kawato Y; Maeda M; Fukahori H; Tsujimoto S; Hirose J; Nakamura K; Marui T; Takamura F; Noto T; Chapin SJ; Fujii Y; Neighbors M; Viswanathan S; Devens BH; Higashi Y
    Transplantation; 2016 Dec; 100(12):2611-2620. PubMed ID: 27861289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oscillatory mTOR inhibition and Treg increase in kidney transplantation.
    Sabbatini M; Ruggiero G; Palatucci AT; Rubino V; Federico S; Giovazzino A; Apicella L; Santopaolo M; Matarese G; Galgani M; Terrazzano G
    Clin Exp Immunol; 2015 Nov; 182(2):230-40. PubMed ID: 26077103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corticosteroids and methotrexate as adjuvants to costimulation blockade in non-human primate renal transplantation.
    Anderson DJ; Lo DJ; Leopardi F; Song M; Strobert EA; Jenkins JB; Larsen CP; Kirk AD
    Clin Transplant; 2019 Jun; 33(6):e13568. PubMed ID: 31006146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
    Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
    Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade.
    Grimbert P; Audard V; Diet C; Matignon M; Plonquet A; Mansour H; Desvaux D; Durrbach A; Cohen JL; Lang P
    Nephrol Dial Transplant; 2011 Mar; 26(3):1087-93. PubMed ID: 20667993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of Belatacept on virus-specific memory versus de novo allo-specific T cell responses of kidney transplant recipients and healthy donors.
    Kühne JF; Neudörfl C; Beushausen K; Keil J; Malysheva S; Wandrer F; Haller H; Messerle M; Blume C; Neuenhahn M; Schlott F; Hammerschmidt W; Zeidler R; Falk CS
    Transpl Immunol; 2020 Aug; 61():101291. PubMed ID: 32330566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation.
    Zhang H; Wang Z; Zhang J; Gui Z; Han Z; Tao J; Chen H; Sun L; Fei S; Yang H; Tan R; Chandraker A; Gu M
    Front Immunol; 2021; 12():618737. PubMed ID: 33732243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
    Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB
    PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model.
    Samy KP; Anderson DJ; Lo DJ; Mulvihill MS; Song M; Farris AB; Parker BS; MacDonald AL; Lu C; Springer TA; Kachlany SC; Reimann KA; How T; Leopardi FV; Franke KS; Williams KD; Collins BH; Kirk AD
    Am J Transplant; 2017 May; 17(5):1193-1203. PubMed ID: 27888551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alloreactive CD154-expressing T-cell subsets with differential sensitivity to the immunosuppressant, belatacept: potential targets of novel belatacept-based regimens.
    Ashokkumar C; Ganguly B; Townsend R; White J; Levy S; Moritz M; Mazariegos G; Sun Q; Sindhi R
    Sci Rep; 2015 Oct; 5():15218. PubMed ID: 26472085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.
    Ferguson R; Grinyó J; Vincenti F; Kaufman DB; Woodle ES; Marder BA; Citterio F; Marks WH; Agarwal M; Wu D; Dong Y; Garg P
    Am J Transplant; 2011 Jan; 11(1):66-76. PubMed ID: 21114656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model.
    D'Addio F; Yuan X; Habicht A; Williams J; Ruzek M; Iacomini J; Turka LA; Sayegh MH; Najafian N; Ansari MJ
    Transplantation; 2010 Aug; 90(3):260-9. PubMed ID: 20712076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation.
    Macedo C; Walters JT; Orkis EA; Isse K; Elinoff BD; Fedorek SP; McMichael JM; Chalasani G; Randhawa P; Demetris AJ; Zeevi A; Tan H; Shapiro R; Landsittel D; Lakkis FG; Metes D
    Transplantation; 2012 Apr; 93(8):813-21. PubMed ID: 22343334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TIGIT regulates apoptosis of risky memory T cell subsets implicated in belatacept-resistant rejection.
    Sun H; Hartigan CR; Chen CW; Sun Y; Tariq M; Robertson JM; Krummey SM; Mehta AK; Ford ML
    Am J Transplant; 2021 Oct; 21(10):3256-3267. PubMed ID: 33756063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Belatacept Conversion on Renal Function, Histology, and Gene Expression in Kidney Transplant Patients With Chronic Active Antibody-mediated Rejection.
    Kumar D; Raynaud M; Chang J; Reeve J; Yakubu I; Kamal L; Levy M; Bhati C; Kimball P; King A; Massey D; Halloran P; Gupta G
    Transplantation; 2021 Mar; 105(3):660-667. PubMed ID: 32510913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients.
    Hoerning A; Köhler S; Jun C; Lu J; Fu J; Tebbe B; Dolff S; Feldkamp T; Kribben A; Hoyer PF; Witzke O
    Clin Exp Immunol; 2012 May; 168(2):251-9. PubMed ID: 22471287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.